Home/Filings/4/0001209191-14-018066
4//SEC Filing

Insys Therapeutics, Inc. 4

Accession 0001209191-14-018066

CIK 0001516479operating

Filed

Mar 5, 7:00 PM ET

Accepted

Mar 6, 7:03 PM ET

Size

32.0 KB

Accession

0001209191-14-018066

Insider Transaction Report

Form 4
Period: 2014-03-05
Dillaha Larry
Chief Medical Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2014-03-05$10.89/sh+18,750$204,18821,875 total
  • Exercise/Conversion

    Common Stock

    2014-03-05$3.54/sh+19,056$67,45840,931 total
  • Sale

    Common Stock

    2014-03-05$72.65/sh97,789$7,104,37155,268 total
  • Sale

    Common Stock

    2014-03-05$83.92/sh653$54,80054,078 total
  • Sale

    Common Stock

    2014-03-05$81.91/sh4,680$383,33948,774 total
  • Sale

    Common Stock

    2014-03-05$79.81/sh3,811$304,15639,246 total
  • Sale

    Common Stock

    2014-03-05$78.59/sh2,304$181,07136,942 total
  • Sale

    Common Stock

    2014-03-05$76.25/sh15,954$1,216,4933,125 total
  • Disposition to Issuer

    Stock Option (right to buy)

    2014-03-0519,05629,944 total
    Exercise: $3.54Exp: 2022-12-26Common Stock (19,056 underlying)
  • Sale

    Common Stock

    2014-03-05$82.55/sh624$51,51153,454 total
  • Sale

    Common Stock

    2014-03-05$77.24/sh17,863$1,379,73819,079 total
  • Disposition to Issuer

    Stock Option (right to buy)

    2014-03-0518,75081,250 total
    Exercise: $10.89Exp: 2023-05-13Common Stock (18,750 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2014-03-05112,1260 total
    Exercise: $1.83Exp: 2020-04-04Common Stock (112,126 underlying)
  • Exercise/Conversion

    Common Stock

    2014-03-05$1.83/sh+112,126$205,191153,057 total
  • Sale

    Common Stock

    2014-03-05$84.72/sh537$45,49554,731 total
  • Sale

    Common Stock

    2014-03-05$80.25/sh5,717$458,78943,057 total
Footnotes (13)
  • [F1]Includes 3,125 shares acquired by the Reporting Person on December 11, 2013 pursuant to the Issuer's Employer Stock Purchase Plan.
  • [F10]The weighted average sales price for the transaction reported was $76.25, and the range of prices were between $75.90 and $76.90.
  • [F11]The option vests in 48 equal monthly installments and will be fully vested and exercisable on May 14, 2017.
  • [F12]The option vests in 36 equal monthly installments and will be fully vested and exercisable on December 27, 2015.
  • [F13]The option is fully vested and exercisable.
  • [F2]The weighted average sales price for the transaction reported was $84.72, and the range of prices were between $84.40 and $85.00.
  • [F3]The weighted average sales price for the transaction reported was $83.92, and the range of prices were between $83.38 and $84.27.
  • [F4]The weighted average sales price for the transaction reported was $82.55, and the range of prices were between $82.14 and $83.00.
  • [F5]The weighted average sales price for the transaction reported was $81.91, and the range of prices were between $81.12 and $82.12.
  • [F6]The weighted average sales price for the transaction reported was $80.25, and the range of prices were between $80.09 and $80.93.
  • [F7]The weighted average sales price for the transaction reported was $79.81, and the range of prices were between $79.08 and $80.08.
  • [F8]The weighted average sales price for the transaction reported was $78.59, and the range of prices were between $78.00 and $79.00.
  • [F9]The weighted average sales price for the transaction reported was $77.24, and the range of prices were between $76.92 and $77.84.

Issuer

Insys Therapeutics, Inc.

CIK 0001516479

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001516479

Filing Metadata

Form type
4
Filed
Mar 5, 7:00 PM ET
Accepted
Mar 6, 7:03 PM ET
Size
32.0 KB